Genetics and Alzheimer’s Disease: A Comprehensive Briefing

Executive Summary

The relationship between genetics and Alzheimer’s disease is categorized by two distinct pathways: risk genes, which increase the probability of developing the disease, and deterministic genes, which directly cause it. Deterministic genes are rare, accounting for less than 5% of all Alzheimer’s cases, and are primarily associated with young-onset (familial) Alzheimer’s. In contrast, the most common form of the disease—late-onset or sporadic Alzheimer’s—develops after age 65 and results from a complex interplay of multiple risk genes, lifestyle choices, and environmental factors.

The most significant genetic risk factor identified is the APOE e4 variant, which can increase risk by up to 12 times in individuals carrying two copies. However, possessing risk genes does not guarantee a diagnosis, nor does their absence ensure immunity. Clinical genetic testing is generally reserved for rare familial cases where symptoms appear before age 65. Experts strongly discourage direct-to-consumer testing due to its limited predictive value and the psychological risks involved. Current research highlights the emerging roles of epigenetics and sex-specific inheritance patterns, particularly the increased risk associated with maternal history.

--------------------------------------------------------------------------------

I. Genetic Framework: Risk vs. Deterministic Genes

Research identifies two primary ways genes influence Alzheimer’s pathology. It is critical to distinguish between these to understand individual susceptibility.

• Risk Genes (Susceptibility Genes): These increase the likelihood of developing Alzheimer's but do not guarantee it. They are common in "sporadic" Alzheimer's, where disease development depends on a combination of genetics, environment, and lifestyle.
• Deterministic Genes: These are rare genetic mutations that directly cause the disease. Inheriting a deterministic gene from either parent nearly guarantees that an individual will develop symptoms, typically before age 65.

Genetic Inheritance Patterns

Inheritance Type

Description

Frequency

Autosomal Dominant

Found in familial Alzheimer's; if one parent has the mutation, children have a 50% chance of inheriting it.

<5% of cases

Complex/Multifactorial

Found in sporadic Alzheimer's; involves multiple risk variants and environmental interactions.

>95% of cases

--------------------------------------------------------------------------------

II. Late-Onset (Sporadic) Alzheimer's Disease

Late-onset Alzheimer’s typically manifests after age 65. While aging is the single greatest risk factor, several genes contribute to susceptibility.

The Role of APOE

The apolipoprotein E (APOE) gene on chromosome 19 is the most studied risk gene. It exists in three common variants:

• APOE e2: The rarest form; appears to provide protection against the disease.
• APOE e3: The most common form; neutral impact on risk.
• APOE e4: Increases risk and is linked to an earlier age of onset and more severe symptoms.

Impact of APOE e4 on Risk:

• One copy: Inheriting one e4 variant from a parent triples the risk of developing Alzheimer's.
• Two copies: Inheriting two copies (one from each parent) increases the risk by 8 to 12 times.

Additional Risk Genes

Researchers have identified over 70 other genes linked to late-onset Alzheimer’s. Key examples include:

• ABCA7: Linked to how the brain utilizes cholesterol.
• CLU: Involved in clearing beta-amyloid (harmful protein fragments) from the brain.
• CR1: Deficiency in the protein created by this gene may cause chronic brain inflammation.
• PICALM: Important for memory and how neurons communicate; also involved in beta-amyloid clearance.
• TREM2: Rare variants increase risk by affecting the brain's inflammatory response.
• SORL1: Plays a role in beta-amyloid production; certain forms are linked to increased risk.

--------------------------------------------------------------------------------

III. Early-Onset (Familial) Alzheimer's Disease

Early-Onset Familial Alzheimer’s Disease (EOFAD) affects individuals between the ages of 30 and 60. It is almost entirely caused by deterministic mutations in three specific genes:

1. Amyloid Precursor Protein (APP): Located on chromosome 21.
2. Presenilin 1 (PSEN1): Located on chromosome 14. This is the most common cause of EOFAD, accounting for 80% of familial cases.
3. Presenilin 2 (PSEN2): Located on chromosome 1.

These mutations lead to an abnormal buildup of amyloid plaques and tau tangles, which result in nerve cell death and cognitive decline. If a person does not inherit the specific disease-causing gene, they cannot pass it on to their children.

--------------------------------------------------------------------------------

IV. Genetics in Other Dementias and Conditions

While Alzheimer's is the most common dementia, other forms also have genetic components:

• Frontotemporal Dementia (FTD): Has a stronger genetic link than Alzheimer's. Approximately 30–40% of cases are familial, linked to mutations in genes such as GRN, MAPT, and C9orf72.
• Vascular Dementia: Most cases are sporadic, but a rare form called CADASIL (caused by a mutation in the NOTCH3 gene) is inherited and typically diagnosed around age 50.
• Down’s Syndrome: These individuals have a high risk of Alzheimer's because they possess an extra copy of chromosome 21, which carries the APP gene. This leads to increased beta-amyloid production.

--------------------------------------------------------------------------------

V. Clinical Applications: Genetic Testing and Counseling

Types of Testing

• Diagnostic Testing: Used for symptomatic individuals to confirm if a specific gene mutation is the cause.
• Predictive (Presymptomatic) Testing: Used for asymptomatic individuals with a known familial mutation to determine if they will develop the disease in the future.

Guidelines and Recommendations

Genetic testing for late-onset Alzheimer's (APOE) is generally not recommended in clinical settings because it lacks predictive certainty. However, it is required for patients considering antiamyloid therapies, as carrying the APOE e4 variant increases the risk of side effects.

Expert Cautions:

• Direct-to-Consumer (DTC) Testing: Tests purchased online are discouraged by the Alzheimer Society and medical professionals. They lack the reliability of accredited labs and do not provide necessary medical context.
• Genetic Counseling: Essential for any testing. Counselors address the psychological impact, including the potential for depression or suicidal thoughts upon receiving positive results.
• Insurance and Employment: While UK insurers are currently prohibited from asking for predictive test results, results may still impact applications for disability, long-term care, or life insurance in other jurisdictions.

--------------------------------------------------------------------------------

VI. Emerging Research and Inheritance Observations

Maternal vs. Paternal Influence

Recent studies of cognitively unimpaired adults suggest that maternal history of Alzheimer’s carries a heavier weight in risk assessment.

• A maternal history of memory loss at any age is associated with higher amyloid levels in offspring.
• A paternal history is only associated with higher amyloid levels if the father had an early onset of symptoms.

Epigenetics

Epigenetics involves changes in gene expression that do not alter the DNA sequence itself.

• DNA Methylation and Histone Modification: These processes can "turn genes on or off."
• Environmental Impact: Early-life trauma, diet, and aging can cause epigenetic shifts that influence dementia risk.
• Therapeutic Potential: Researchers are exploring drugs that target these modifications to "reset" gene expression patterns and restore cognitive function.

--------------------------------------------------------------------------------

VII. Modifiable Risk Factors and Prevention

Evidence emphasizes that genes are not the sole determinant of brain health. Even individuals with a high genetic risk can lower their probability of cognitive decline through lifestyle interventions.

Key Lifestyle Strategies:

• Cardiovascular Health: Reducing risk factors for vascular disease.
• Physical and Mental Activity: Keeping the body and mind active.
• Diet and Habits: Following a healthy diet, avoiding smoking, and limiting alcohol consumption.
• Injury Prevention: Avoiding head injuries.
• Psychological Health: Managing stress and effectively treating depression.

"A person with dementia risk variants is at higher risk... despite this higher risk, they still might never develop dementia." — Alzheimer’s Society Factsheet 405